SecBot SecBot
8-K ·Filed Mar 5, 2026

PROF

Profound Medical Corp.
BULLISH
Impact 7/10
Horizonmonths Processed8mo ago SEC0001171843-26-001362
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The significant revenue growth, expanding installed base, and strong cash position position Profound for potential commercial acceleration in 2026. Upcoming catalysts include the presentation of CAPTAIN trial clinical outcomes at the EAU Congress, which could drive further adoption. Monitor the gross margin trajectory as the company scales and the pace of TULSA-PRO installations throughout 2026.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$5.31
T+0 close · Mar 5, 2026 · via day close
Latest settled
+25.61%
T+60 · $6.67
Vs SPY
+12.83%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 6 $5.31entry
  2. T+1 · 8mo ago −1.51%α −2.35% · $5.23
  3. T+5 · 8mo ago +3.77%α +5.29% · $5.51
  4. T+20 · 8mo ago +23.54%α +25.58% · $6.56
  5. T+60 · 6mo ago +25.61%α +12.83% · $6.67
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Profound Medical reported strong Q4 and full-year 2025 results with 43% YoY revenue growth to $6.0 million and full-year revenue of $16.1 million. The company strengthened its balance sheet with $42.5 million in equity financing, expanded its TULSA-PRO installed base to 78 systems, and expects to reach 120 installs by end of 2026. Despite record revenue, net losses widened to $8.2 million in Q4 and $42.6 million for the year.

Key Financial Metrics

Revenue
$16.1M
+50.5% YoY
EPS
$-1.41
Free Cash Flow
-$38.4M
Gross Margin
71%

Key Facts

  • Q4 2025 revenue: $6.0 million (43% YoY growth)
  • Full-year 2025 revenue: $16.1 million (up from $10.7 million in 2024)
  • TULSA-PRO installed base: 78 systems as of December 31, 2025
  • Company expects to reach approximately 120 TULSA-PRO installs by end of 2026
  • Raised $42.5 million in equity financing in December 2025 ($36M US offering, $6.45M Canadian private placement)
  • Cash balance: $59.7 million as of December 31, 2025
  • Q4 2025 gross margin: 67% (down from 71% YoY due to product mix and introductory pricing)
  • Full-year 2025 gross margin: 71% (up from 66% in 2024)
  • Appointed Frank Baylis to Board of Directors

Financial Impact

Revenue grew from $10.7M in 2024 to $16.1M in 2025 (50.5% increase), while net loss increased from $27.8M to $42.6M. Company raised $42.5M in equity financing.

revenuegross marginnet losscash

Segment Breakdown

SegmentRevenueGrowth
Recurring - non-capital$9.7M+18.1%
Capital equipment$6.4M+161.0%

Risk Factors

  • Continuing net losses despite revenue growth
  • Gross margin pressure in Q4 2025 due to product mix and introductory pricing in new markets
  • Execution risk in scaling commercial operations and achieving the target of 120 installs by end of 2026

Market Snapshot

Exchange
Nasdaq

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001171843-26-001362
Document: f8k_030526.htm0001171843-26-001362
Document: 0001171843-26-001362-index-headers.html0001171843-26-001362
Document: 0001171843-26-001362-index.html0001171843-26-001362
Document: 0001171843-26-001362.txt0001171843-26-001362

US Market Status

Market Closed · Opens Wed (9h 59m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 5, 2026